Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition.

Slides:



Advertisements
Similar presentations
HEMOSTASIS Hemostasis
Advertisements

03/06/231 K June /06/232 Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Low HDL Epidemiological Studies (e.g. Framingham) Genetic.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Aggrenox Is it as good as the ads?. ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602.
Chapter 13 Leukocyte Activation and Migration Dr. Capers
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:
Prostaglandins& Related Compounds. Objectives Origin of ecosanoids Ecosanoids role Overview of the structure Role of phospholipase A2 Cyclooxgenase isoenzymes.
Chemical Mediators and Regulators of Inflammation 1 Dr. Hiba Wazeer Al Zou’bi.
ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602 patients randomized within 3 months.
Inflammation The process of inflammation initiates from tissue injury or from foreign presence its initiation is triggered by the production of: a) chemokine.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Effects of Exposure to Cigarette.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.
Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Sonic Hedgehog-Induced Functional Recovery After.
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Fatty Acids and Cardiovascular Disease: Effects.
Date of download: 6/3/2016 Copyright © American College of Chest Physicians. All rights reserved. Tissue Factor, Thrombin, and Cancer * Chest. 2003;124(3_suppl):58S-68S.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic interaction of naproxen with low-dose.
Prostaglandins& Related Compounds. Objectives Origin of ecosanoids Ecosanoids role Overview of the structure Role of phospholipase A2 Cyclooxgenase isoenzymes.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Frequency and Practice-Level Variation in Inappropriate.
Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy-associated plasma protein-A levels in.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.
Date of download: 6/23/2016 From: Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates Ann Intern Med. 1993;119(12):
Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Vascular Inflammation and Repair: Implications for.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comparative effects of AT1-antagonism and angiotensin-converting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Modified Serum Profiles of Inflammatory and Vasoconstrictive.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Platelet Biology and Response to Antiplatelet Therapy.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacologic plaque passivation for the reduction.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin and Cancer J Am Coll Cardiol. 2016;68(9):
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Peroxisome Proliferator-Activated Receptor-γ.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin and Cancer J Am Coll Cardiol. 2016;68(9):
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the.
A. Mechanism of action of aspirin
Copyright © 2012 American Medical Association. All rights reserved.
Inflammation lecture 4 Dr Heyam Awad FRCPath.
Copyright © 2003 American Medical Association. All rights reserved.
Cell-Derived Inflammatory Mediators
Chemical Mediators Dr Shoaib Raza.
Figure 1 Mechanism of thrombus formation during ST-segment
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Nat. Rev. Cardiol. doi: /nrcardio
Thrombosis and Inflammatory Bowel Disease
Figure 1 Relationships between magnitude of antithrombotic benefit vs
Clinical Gastroenterology and Hepatology
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Presentation transcript:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin J Am Coll Cardiol. 2015;66(1): doi: /j.jacc Platelet Inhibition by Low-Dose Aspirin A wide repertoire of lipid and protein mediators, which may contribute to several clinical syndromes possibly responsive to low- dose aspirin therapy, are released upon platelet activation and aggregation. The figure illustrates inhibition of platelet prostanoid production by aspirin and its functional and clinical consequences. The lines of evidence supporting the protective effects of aspirin are summarized below each panel. AA = arachidonic acid; ASPREE = ASPirin in Reducing Events in the Elderly; RCT = randomized controlled trial(s); PGE2 = prostaglandin E2; PGH2 = prostaglandin H2; TXA2 = thromboxane A2. Figure Legend:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin J Am Coll Cardiol. 2015;66(1): doi: /j.jacc Absolute Effects of Antiplatelet Therapy With Low-Dose Aspirin on the Risk of Vascular Events (Nonfatal MI, Nonfatal Stroke, or Death From Vascular Causes) in 5 Groups of High-Risk Patients The number needed to treat (NNT) ranged between 26 (acute myocardial infarction [MI]) to 100 (acute stroke) per month of treatment in the acute setting, and from 65 (previous MI) to 105 (previous stroke) per year of treatment in the secondary prevention setting. Figure Legend:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin J Am Coll Cardiol. 2015;66(1): doi: /j.jacc Benefits and Risks of Low-Dose Aspirin in Primary Prevention Trials The numbers of vascular events avoided and episodes of major bleeding caused per 1,000 patients treated with aspirin per year are plotted from the results of individual placebo-controlled trials of aspirin in different patient populations characterized by various degrees of cardiovascular risk, as noted on the abscissa. Number needed to treat (NNT) and number needed to harm (NNH) values are given for subjects in 3 categories of risk on the basis of the presence or absence of randomized controlled trials. Modified with permission from Patrono et al. (5). ACCEPT-D = Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes; ASCEND = A Study of Cardiovascular Events in Diabetes; ARRIVE = Aspirin to Reduce Risk of Initial Vascular Events; ASPREE = ASPirin in Reducing Events in the Elderly; BDT = British Doctors Trial; HOT = Hypertension Optimal Treatment Study; PHS = Physicians’ Health Study; PPP = Primary Prevention Project; SAPAT = Swedish Angina Pectoris Aspirin Trial; TPT = Thrombosis Prevention Trial; WHS = Women’s Health Study. Figure Legend:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin J Am Coll Cardiol. 2015;66(1): doi: /j.jacc Platelet-Derived Mediators of the Inflammatory Response Activated platelets release inflammatory and mitogenic substances into the microenvironment, primarily altering the chemotactic, adhesive, and proteolytic properties of the endothelium. Pre-formed platelet mediators, stored in α-granules, can be released immediately after platelet activation through a process of exocytosis triggered by increased intracellular calcium levels. Activated platelets are also capable of time-dependent synthesis of protein mediators, such as tissue factor and interleukin-1β. CD40 ligand is stored in the cytoplasm of resting platelets and rapidly presents on the surface after platelet activation. After cleavage, to generate a soluble, functional fragment (soluble CD40 ligand), the mediator is released into the extracellular environment, inducing inflammatory responses in the endothelium by binding CD40 on endothelial cells. P-selectin is released from platelet granules and binds to the P-selectin glycoprotein ligand 1 (PSGL-1) receptor on monocytes, enhancing the adhesion of the monocytes to vascular-cell adhesion molecule (VCAM) 1 and the other adhesins expressed on activated endothelial cells and inducing the production of tissue factor by monocytes. Activated platelets also release chemokines that trigger the recruitment of monocytes (e.g., regulated on activation normal T-cell expressed and secreted [RANTES]) or promote the differentiation of monocytes into macrophages (e.g., platelet factor 4), as well as matrix-degrading enzymes such as matrix metalloproteinase (MMP) 2 or 9. Interleukin-1β is a major mediator of platelet-induced activation of endothelial cells, causing enhanced chemokine release and up- regulation of endothelial adhesion molecules to promote the adhesion of neutrophils and monocytes to the endothelium. H2O2 = hydrogen peroxide; ICAM = intracellular adhesion molecule; mRNA = messenger RNA; MCP = monocyte chemoattractant protein; O2– = superoxide anion; OH – = hydroxyl radical. Figure Legend: